Daewoong Pharmaceutical acquires preferential sale right in KRW 150 billion hepatitis B generic market

Published: 2017-09-15 15:27:34

Updated: 2017-09-15 15:27:55

Daewoong Pharmaceutical will enter the market of ‘tenofovir,’ a hepatitis B treatment, worth of approximately KRW 150 billion.

Daewoong Pharmaceutical(CEO Jong-Wook Lee) announced on the 14^th that ‘Virihepa,’ its hepatitis B treatment containing the ‘tenofovir’ substance, acquired the preferential sale right from the Ministry of Food and Drug Safety(MFDS). Virihepa is expected to be launched o...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.